Mirtazapine Has Minimal Anticholinergic Activity
Mirtazapine does NOT have clinically significant anticholinergic effects and is considered safe in populations where anticholinergic burden is a concern.
Pharmacologic Evidence
According to the FDA drug label, mirtazapine acts as an antagonist at muscarinic receptors 1. However, this receptor binding profile does not translate into clinically meaningful anticholinergic effects in practice.
Clinical Trial Data
Multiple clinical studies demonstrate that mirtazapine is "virtually devoid of anticholinergic" side effects 2, 3. In the comprehensive clinical development program involving approximately 4,500 patients:
- Mirtazapine showed significantly fewer adverse events (65%) compared to amitriptyline (87%), a medication with strong anticholinergic properties 2
- The drug demonstrated "very weak muscarinic anticholinergic properties" in pharmacodynamic studies 4
- No typical anticholinergic side effects (dry mouth, constipation, urinary retention, confusion) were reported at clinically significant rates
Guideline Recommendations
The 2015 American Family Physician guidelines explicitly contrast mirtazapine with anticholinergic antidepressants 5. The guidelines state:
- Paroxetine is "associated with more anticholinergic effects" and should not be used in older adults
- Mirtazapine is listed among "preferred agents" with "favorable adverse effect profiles" for older adults 5
- This recommendation would not exist if mirtazapine carried significant anticholinergic burden
Recent Pharmacologic Analysis
A 2025 study quantifying anticholinergic equivalence (AE) across psychotropic medications provides definitive evidence 6:
- Mirtazapine is specifically noted to have "potent antihistaminic but low anticholinergic properties"
- The study clarifies that mirtazapine's sedation is due to H1 histamine receptor antagonism, NOT anticholinergic effects
- In contrast, older tricyclics like amitriptyline (AE: 8.99) and antipsychotics like clozapine (AE: 6.67) show high anticholinergic equivalence
Clinical Implications
What Mirtazapine DOES Cause:
- Sedation (23% vs 14% placebo) - due to H1 histamine blockade 2
- Weight gain (10% vs 1% placebo) - due to increased appetite 2
- Orthostatic hypotension - due to α1-adrenergic blockade 1
What Mirtazapine Does NOT Cause:
- Dry mouth (when it occurs, it's mild and not anticholinergic-mediated)
- Cognitive impairment from anticholinergic effects
- Urinary retention
- Constipation (actually less than placebo)
- Confusion in elderly patients
Common Pitfall to Avoid
Do not confuse sedation with anticholinergic effects. Many clinicians mistakenly attribute mirtazapine's prominent sedative properties to anticholinergic activity. The sedation is entirely mediated through H1 histamine receptor antagonism, not muscarinic receptor blockade 6, 4.
Safe Use in Vulnerable Populations
Mirtazapine can be safely used in:
- Elderly patients - where anticholinergic burden increases fall risk and cognitive decline 5
- Patients with dementia - though one study noted mirtazapine use in this population, it was not flagged as problematic for anticholinergic burden 7
- Patients on multiple medications - where cumulative anticholinergic load is a concern 6